NCT06794125 An Evaluation of Dose-escalation for Intrathoracic Tumours
| NCT ID | NCT06794125 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chris Goodman |
| Condition | Lung Cancers |
| Study Type | INTERVENTIONAL |
| Enrollment | 141 participants |
| Start Date | 2025-09-03 |
| Primary Completion | 2029-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 141 participants in total. It began in 2025-09-03 with a primary completion date of 2029-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a pragmatic trial with patients randomized between standard of care palliative thoracic radiation therapy (RT) vs. hypofractionated, dose-escalated, esophageal-sparing (HD-ES) intensity modulated radiation therapy (IMRT). The investigators hypothesize that the use of advanced radiation planning techniques to optimize dose to esophagus will permit the safe delivery of a modestly dose-escalated five-fraction course of palliative radiation to intrathoracic malignancies. This approach aims to deliver higher biologically effective doses while improving toxicity when compared to conventional approaches with the goal of prolonging high-quality overall survival.
Eligibility Criteria
Inclusion Criteria: * Intrathoracic tumour requiring palliative radiation, either for palliation of symptoms or prevention of progression that is expected to cause symptoms in the next 6 months (in the judgement of the enrolling investigator) * Willingness and ability to provide informed consent * Eastern Cooperative Oncology Group performance status 0-3 * Age 18 years or older * Prior or planned systemic treatment (chemotherapy, immunotherapy, targeted agents) is permissible at the discretion of the treating medical oncologist * Concurrent palliative radiotherapy to other metastatic sites is permissible at the discretion of the treating radiation oncologist. * Life expectancy greater than 3 months Exclusion Criteria: * Prior thoracic radiotherapy which, in the opinion of the treating of radiation oncologist, precludes the delivery of further thoracic radiotherapy. If there has been prior thoracic radiotherapy, a composite of all RT plans must be created, and the dose constraints herein must still be met. An allowance for 10 percent repair is permitted if at least 12 months have passed between the prior radiotherapy and the trial protocol specified radiotherapy. * Serious medical comorbidities which, in the opinion of the treating radiation oncologist, preclude the delivery of radiotherapy. This includes interstitial lung disease. * Pregnant or lactating women * Inability to attend the full course of radiotherapy or planned follow-up visits
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06794125 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06794125 currently recruiting?
Yes, NCT06794125 is actively recruiting participants. Contact the research team at Chris.Goodman@lhsc.on.ca for enrollment information.
Where is the NCT06794125 trial being conducted?
This trial is being conducted at Kelowna, Canada, London, Canada, Waterloo, Canada.
Who is sponsoring the NCT06794125 clinical trial?
NCT06794125 is sponsored by Chris Goodman. The trial plans to enroll 141 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.